J&J posts promising late-stage data for plaque psoriasis therapy developed with Protagonist

Johnson & Johnson (NYSE:JNJ) on Friday announced favorable data from a Phase 3 trial for icotrokinra (JNJ-2113), its once-daily pill developed with Protagonist Therapeutics (NASDAQ:PTGX) for plaque psoriasis, an immune-mediated skin disorder.

Citing 16-week data from its ICONIC-TOTAL trial conducted